Health & Nutrition

bg
Danaher stock fails to rise on solid earnings — leading us to question what's next

Danaher stock fails to rise on solid earnings — leading...

While the quarter was solid and 2026 is shaping up to be better than 2025, the progress...

bg
How Low Can LDL Cholesterol Go on PCSK9 Inhibitors?

How Low Can LDL Cholesterol Go on PCSK9 Inhibitors?

People with genetic mutations that leave them with an LDL cholesterol of 30 mg/dL...

bg
How to Beat Heart Disease Before It Starts

How to Beat Heart Disease Before It Starts

Why might healthy lifestyle choices wipe out 90% of our risk for having a heart...

bg
What obesity drugmakers see next in the market: More pills, easier access and drug combinations

What obesity drugmakers see next in the market: More pills,...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers...

bg
OpenEvidence, the 'ChatGPT for doctors,' doubles valuation to $12 billion

OpenEvidence, the 'ChatGPT for doctors,' doubles valuation...

OpenEvidence, based in Miami, has topped a $12 billion valuation in a funding round...

bg
Amazon launches AI health-care tool for One Medical members

Amazon launches AI health-care tool for One Medical members

The service uses large language models and references patients medical records to...

bg
Another alliance of health care and AI signals why pharma stocks should be back in favor

Another alliance of health care and AI signals why pharma...

Bristol Myers Squibb and Microsoft's new partnership aimed at accelerating early...

bg
Is Fasting an Effective Treatment for Diabetes?

Is Fasting an Effective Treatment for Diabetes?

By losing 15% of their body weight, nearly 90% of those who have had type 2 diabetes...

bg
All About Allulose

All About Allulose

Sugar and high fructose corn syrup are the original industrial sweeteners—inexpensive,...

bg
Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch

Novo Nordisk shares rise 8% after Wegovy obesity pill has...

The early data is a boost to the Danish drugmaker's hopes of winning back more market...